How long does it take to take Osimertinib tablets before you can consider stopping the drug?

As a third-generation EGFR tyrosine kinase inhibitor, Osimertinib is currently a key targeted drug for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC). There is no "universal" clinical standard for the length of its administration. Whether the drug can be discontinued depends on the patient's disease progression, treatment response, and the doctor's individual judgment. According to current guidelines and overseas treatment strategies, osimertinib is usually used as initial treatment until disease progression or intolerable toxicity occurs.

In the context of adjuvant treatment after surgery, the generally recommended course of treatment is about three years. In patients with advanced or metastatic disease, osimertinib is usually continued until the disease develops drug resistance. Even if some patients achieve complete remission on imaging, stopping the drug may still bring the risk of recurrence. Therefore, the concept of "stopping the drug when cured" is still conservative in the treatment of EGFR mutation-driven lung cancer.

At present, some foreign expert teams are exploring the disease-free survival (DFS) after discontinuation of osimertinib, and are trying to combine biomarkers such as ctDNA to determine the minimal residual disease, and make decisions on whether to extend or discontinue the drug based on this. It is worth noting that hasty voluntary discontinuation of medication may lead to an increased risk of relapse or drug resistance. When considering discontinuation of medication, patients should always have professional oncologists make arrangements based on comprehensive judgment, and patients cannot stop treatment on their own based on disappearance of symptoms or improvement in imaging.

At the same time, regular imaging review and molecular testing can also help doctors evaluate whether to maintain the original treatment plan or make adjustments. With the development of precision medicine, research on the individualized management of osimertinib treatment is also deepening. In the future, there may be clearer biological indicators to guide the timing of drug discontinuation.

Reference materials:https://go.drugbank.com/drugs/DB09330